LegalNewsLine Logo  
Friday, February 10 2012 Twitter  feedburner  yahoo  Subscribe in NewsGator Online
News | Contact LegalNewsline | About Us | Advertise | RSS
Enter search keyword
 
clear
clear
NEWSLETTER
Receive our FREE weekly newsletter
click here
Today's Offers:

LNL MOST POPULAR ARTICLES
+ Hood critical of bill that would allow officials to hire outside attorneys
+ More than 40 states have signed on to proposed mortgage deal
+ Study shows plaintiff bias in Philly courts
+ Man, startled by bottle rocket shot out of anus, sues frat
+ Real estate agent, mortgage broker found guilty of fraud
LNL HOT TOPICS
+ Asbestos
+ Big Pharma
+ BP Oil Spill
+ Class Action
+ Dickie Scruggs
+ Federal Government
+ Financial Crisis
+ Global Warming
+ Hurricane Katrina
+ Lead Paint
+ Sub-Prime Mortgages
+ Tobacco
State Supreme Courts 
story date  
Outcome of Nexium suit could give plaintiffs heartburn
wills.jpg
Wills
LITTLE ROCK, Ark. (Legal Newsline) - The Arkansas Supreme Court has affirmed the dismissal of a lawsuit against AstraZeneca Pharmaceuticals, deciding that nine plaintiffs haven't suffered any harm because of the company's marketing of Nexium.

Associate Justice Elana Cunningham Wills and the Court agreed with the decision by Searcy County Circuit Judge Michael Maggio, who said the plaintiffs' complaint was well-researched but provided "little or no proof" that AstraZeneca had committed an actionable tort.

The plaintiffs alleged that AstraZeneca marketed Nexium as superior to Prilosec, a similar heartburn drug produced by the company that had its patent expire in 2001.

Nexium's labeling had been approved by the Food and Drug Administration.

"The information included in the labeling of a new drug reflects a determination by the FDA that the information is not 'false or misleading,'" Wills wrote Nov. 5.

"By approving information to be included in the drug labeling, the FDA has determined that the information complies with its rules and regulations. Therefore, if the FDA labeling supports the statements made in the advertising for an FDA-approved drug, the statements are not actionable under the (Arkansas Deceptive Trade Practices Act)."

Attorneys James Beck and Mark Herrmann, on their blog Drug and Device Law, said the only worthwhile recovery in the suit would have been for attorneys fees.

Beck and Herrmann said the case was significant because Arkansas' became the first state supreme court decision to "affirm the dismissal of a consumer fraud action against an FDA-regulated defendant based upon a safe harbor provision relating to government-regulated conduct."

The safe harbor provision of state consumer protection law bars companies from being sued for conduct approved by a federal or state regulatory agency. Beck and Herrmann say the concept also shows up in the laws of Connecticut, Florida, Indiana, Maine, Masssachusetts, Montana, Nebraska, New Mexico, Ohio, Rhode Island, South Carolina, South Dakota, Utah, Washington, and Wyoming.

From Legal Newsline: Reach John O'Brien by e-mail at jobrienwv@gmail.com.

Filed Under: State Supreme Courts

E-mail this article to a friend | Printer friendly format

MORE NEWS HEADLINES:
+ W.Va. SC says city can't be sued for injuries at trash station - 2/10   read more
+ S.C. chief justice says courts essential to economic development - 2/9   read more
+ Pa. SC won't meddle with Philly forum-shopping - 2/2   read more
+ D.C. high court tackles government contacts principle - 2/2   read more
+ Conn. SC: Physician's opinion in med mal case detailed enough - 2/1   read more
+ Ark. SC rules clerk's signature on summons was valid - 2/1   read more
+ Miss. SC reverses part of decision in underwriting case - 2/1   read more
+ Mo. SC upholds cap on punitive damages - 1/31   read more
+ Del. SC says firm's fee must be deducted before lien - 1/31   read more
+ Md. high court: Allergy is a handicap - 1/31   read more


IN THE SPOTLIGHT:
garrett.jpg
Wednesday, February 08, 2012
PHILADELPHIA (Legal Newsline) - A roundtable of federal and state judges from across the country will convene at the posh Ritz Carlton on Feb. 9 to address topics such as "Can MDL's keep up with state court trial settings;" "Priority of deposition examination;" "State and federal cooperation;" and "Forum non conveniens."
Read more...


+ Study shows plaintiff bias in Philly courts - 2/6
+ Fannie Mae offers examples of routine dishonesty in its fight against lenders - 2/3
+ Quaker City courts have troubled history; some reject 'plaintiff-friendly' criticism - 1/31
+ Madison County asbestos docket feeds off intake firm referrals - 1/19
+ Torts conference set for Feb. 8 in Philly - 1/18
BROWSE BY STATE:
 
BROWSE BY AG:
 
BROWSE BY DATE:
 
NEWS WIDGET:
Attention bloggers:
Add Record Headlines to your site!


fast + free- click here
NEWS | CONTACT LEGALNEWSLINE | ABOUT US | ADVERTISE | RSS © 2008 LegalNewsLine.com. All Rights Reserved.